# PROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLC

> **NCT06977074** · PHASE2 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 83 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer (NSCLC)

## Interventions

- **DRUG:** PD-1 inhibitor
- **DRUG:** Platinum Doublet

## Key facts

- **NCT ID:** NCT06977074
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-10
- **Primary completion:** 2028-05-10
- **Final completion:** 2030-05-10
- **Target enrollment:** 83 (ESTIMATED)
- **Last updated:** 2025-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06977074

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06977074, "PROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLC". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06977074. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*